1. Home
  2. OGEN vs IDAI Comparison

OGEN vs IDAI Comparison

Compare OGEN & IDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OGEN
  • IDAI
  • Stock Information
  • Founded
  • OGEN 1996
  • IDAI 2016
  • Country
  • OGEN United States
  • IDAI United States
  • Employees
  • OGEN N/A
  • IDAI N/A
  • Industry
  • OGEN Biotechnology: Pharmaceutical Preparations
  • IDAI Computer Software: Prepackaged Software
  • Sector
  • OGEN Health Care
  • IDAI Technology
  • Exchange
  • OGEN Nasdaq
  • IDAI Nasdaq
  • Market Cap
  • OGEN 4.6M
  • IDAI 5.0M
  • IPO Year
  • OGEN N/A
  • IDAI N/A
  • Fundamental
  • Price
  • OGEN $4.28
  • IDAI $2.04
  • Analyst Decision
  • OGEN
  • IDAI
  • Analyst Count
  • OGEN 0
  • IDAI 0
  • Target Price
  • OGEN N/A
  • IDAI N/A
  • AVG Volume (30 Days)
  • OGEN 599.0K
  • IDAI 46.6K
  • Earning Date
  • OGEN 05-09-2025
  • IDAI 05-15-2025
  • Dividend Yield
  • OGEN N/A
  • IDAI N/A
  • EPS Growth
  • OGEN N/A
  • IDAI N/A
  • EPS
  • OGEN N/A
  • IDAI N/A
  • Revenue
  • OGEN N/A
  • IDAI $3,054,143.00
  • Revenue This Year
  • OGEN N/A
  • IDAI $65.46
  • Revenue Next Year
  • OGEN N/A
  • IDAI $12.00
  • P/E Ratio
  • OGEN N/A
  • IDAI N/A
  • Revenue Growth
  • OGEN N/A
  • IDAI N/A
  • 52 Week Low
  • OGEN $3.12
  • IDAI $1.43
  • 52 Week High
  • OGEN $75.60
  • IDAI $18.75
  • Technical
  • Relative Strength Index (RSI)
  • OGEN 43.10
  • IDAI 44.42
  • Support Level
  • OGEN $3.12
  • IDAI $2.05
  • Resistance Level
  • OGEN $9.60
  • IDAI $2.32
  • Average True Range (ATR)
  • OGEN 1.04
  • IDAI 0.15
  • MACD
  • OGEN -0.12
  • IDAI -0.02
  • Stochastic Oscillator
  • OGEN 17.90
  • IDAI 9.01

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

About IDAI T Stamp Inc.

T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.

Share on Social Networks: